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Background: Congenital heart defects (CHD) represent one of the most common birth defects. This study aimed
to evaluate the value of multiplex ligation-dependent probe amplification (MLPA) as a tool to detect the copy
number variations (CNVs) of 22q11 in fetuses with CHD.
Results: A large cohort of 225 fetuses with CHD was screened by fetal echocardiography. Once common chromosome
abnormalities in 30 fetuses were screened out by conventional G-banding analysis, the CNVs of chromosome 22q11 in
the remaining 195 fetuses were determined by MLPA for prenatal genetic counseling. In 195 CHD fetuses with normal
karyotype, 11 cases had pathological CNVs, including 22q11.2 deletion (seven cases), the deletion of 22q11 cat eye
syndrome (CES) region (one case), 22q11.2 duplication (one case), 22q13.3 deletion (one case) and 17p13.3 deletion
(one case). In total, our findings from MLPA screening represented 4.9 % in our cohort. Among these, three cases were
inherited CNVs, and eight cases were de novo. These CNVs were further verified by single nucleotide polymorphism
(SNP)-array analysis, and their chromosomal location was refined.
Conclusion: This study indicated that MLPA could serve as an effective test for routine prenatal diagnosis of 22q11 in
fetuses with CHD.
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Congenital heart defects (CHD) usually refer to the ab-
normalities in the heart’s structure or function that arise
before birth [1]. It represents the most frequent birth
defects and the leading cause of death from a congenital
structural abnormality worldwide, causing more than
220,000 deaths globally every year [2]. In China, epidemio-
logical studies have suggested a noticeable increase in
trend of CHD mortality with the overall mortality rate
increasing from 141 in 2003 to 229 in 2010 per 10,000,000
person-years [3].* Correspondence: njfybjyhuping@163.com; zhengfeng_xu_nj@163.com
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current studies have indicated a multiple interaction
between genetic and environmental factors. Specifically,
associations between CHD and chromosomal abnormal-
ities have been well recognized, which accounts for about
16 ~ 56 % of CHD [4]. Moreover, copy number variants
(CNVs) have also been identified as a significant factor in
CHD development and the most common example is the
22q11 deletion syndrome, which is estimated to affect
approximately 1/4000 to 1/6000 in live births [5, 6]. In
China, fetal echocardiography is performed after the
second trimester ultrasound screening. It is well known
that abnormal ultrasound finding is one of most common
indications for amniocentesis or other invasive examin-
ation [7, 8]. Therefore, the amniocentesis or cordocentesisis distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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CNVs for fetuses with CHD.
Conventional fluorescence in situ hybridization (FISH)
with commercial probes (TUPLE1 or N25) has been de-
veloped for the prenatal diagnosis of 22q11 chromosome
deletion by many prenatal services. Mademont-soler
et al. [9] compared FISH and MLPA techniques for
detection of 22q11 chromosome deletion. The results
showed that the use of MLPA had not increased the
number of diagnosis of 22q11 deletion, and the author
suggested that MLPA should not replace FISH as a
conventional technology for prenatal diagnosis of 22q11
chromosome deletion. However, many reports have
pointed out the advantage of MLPA in the postnatal
study [10–12]. To date, there is little data about using
MLPA in a large cohort prenatal study. In our report, we
present a large cohort of 225 CHD fetuses to evaluate
the application value of MLPA in prenatal detection of
CNVs in 22q11.
Results
Conventional G-banding analysis detected all 225
fetuses, and then MLPA screening was performed in the
remaining fetuses with normal karyotype. In total,
chromosomal abnormalities represented 30 cases (13.3 %)
in our cohort (Table 1), including 11 fetuses with trisomy
18, 14 fetuses with trisomy 21, one fetus with 45, XO, two
fetuses with chromosomal polyploidy, one fetus with 46,
XY, add(1) (p36) and one fetus with balanced transloca-
tion (46, XY, t(1;2) (p32;q35)) respectively. Of 30 cases
with chromosomal abnormalities, 19 cases had isolated
CHD and 11 cases had multiple congenital anomalies.
For remaining 195 CHD fetuses with normal karyotype,
MLPA analysis revealed that 11 cases had CNVs (Table 1).
All the 11 cases had isolated CHD, including ten cono-
truncal defects and one septal defect (Table 1). Fe-
tuses 1–6 showed typical 22q11.2 deletions located
from LCR-A to LCR-D regions, fetus seven showed
22q11.2 deletions located from LCR-A to LCR-B re-
gions, and fetus eight showed the deletion based on
the 22q11 cat eye syndrome region while Fetus 9–11Table 1 Summary of aneuploidy and CNVs detected from 225 fetus









Conotruncal defect 85 8 6 1
Septal defect 104 17 1 0
Left-heart defect 7 0 0 0
Right-heart defect 1 0 0 0
Other heart defect 28 5 0 0
Total 225 30 (13.3 %) 7 (3.1 %) 1
CHD congenital heart defects, CNVs copy number variants, CES cat eye syndromeshowed 22q11.2 duplication, 22q13.3 deletion, and
17p13.3 deletion, respectively (Fig. 1) (Table 2). Succedent
SNP-array analysis verified all of the positive results from
MLPA and the concordance rate is 100 % (Table 2). For
fetus 8, SNP-array analysis revealed a 980 kb heterozygous
deletion mapping to position 17,067,005-18,047,231 on
chromosome 22q11 (Fig. 2). Further study indicated that
each CNV of fetuses 7–9 were inherited from one’s
asymptomatic mother or father, while the others were
de novo.
Discussion
In this study, a large cohort of 225 fetuses with CHD
was detected by traditional karyotyping and MLPA to
identify the chromosome abnormality and CNVs on
chromosome 22q11. The results demonstrated 30
fetuses (13.3 %) had a chromosomal abnormality, and 11
fetuses (4.9 %) had CNVs. All positive findings from
MLPA were in agreement with those from SNP-array.
Our study used the MLPA P250 DiGeorge kit to identify
the CNVs on different chromosomes and found that 3.1 %
of CHD cases (7/225) had deletions on 22q11 (Table 1).
Several studies have also reported the frequency of 22q11
CNVs in CHD fetuses and the data ranged from 1.6 ~
11.5 % [4, 13]. Our data was similar to that reported by
Moore et al. [14] (17/540, 3.1 %). Of the seven cases with
22q11 deletions, six cases had conotruncal defects. Our
results showed high detection rate of 22q11 CNVs in cases
with a conotruncal defect (7.1 %, 6/85), which was close to
the findings by Galindo et al. [15] (8.7 %) and Bretelle et al.
[16] (4.7 %). All these results indicated that the conotrun-
cal defect was mostly associated with 22q11 CNVs [15].
In addition to 22q11, MLPA P250 DiGeorge kit also
contains the probes targeting other regions including
22q13, 10p14, 8p23, 9q34, 17p13.3 and 4q34. Thus, we
also found the deletions in both 22q13.3 and 17p13.3
(Table 2). The 22q13.3 deletion syndrome was also de-
fined as a Phelan-McDermid syndrome and mainly man-
ifested as global developmental delay, hypotonia, delayed
or absent speech, and autistic behavior [17, 18]. Only
one study [19] reported one CHD fetus with 22q13.3es with CHD









1 1 1 18
0 0 0 18
0 0 0 0
0 0 0 0
0 0 0 5
(0.4 %) 1 (0.4 %) 1 (0.4 %) 1 (0.4 %) 41 (17.8 %)
Fig. 1 (See legend on next page.)
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Fig. 1 MLPA analysis of chromosome 22q11 in fetuses 1–11. Probe names are shown on the x-axis. Their chromosomal location is displayed in the
upper panel. Columns corresponding to normalized electropherogram peak areas were calculated using Coffalyser software. a. Typical 22q11.2 deletions
located from LCR-A to LCR-D regions in fetus 1–6. b. 22q11.2 deletions located from LCR-A to LCR-B regions in fetus 7. c. The deletion located in the
22q11 cat-eye-syndrome region in fetus 8. d. 22q11.2 duplication in fetus 9. e. 22q13.3 deletion in fetus 10. f. 17p13.3 deletion in fetus 11
Zhang et al. Molecular Cytogenetics  (2015) 8:100 Page 4 of 7deletion by prenatal diagnosis, supporting the findings of
our study. The 17p13.3 deletion syndrome is also known
as Miller-Dieker Lissencephaly Syndrome. The syndrome
is characterized by nervous system anomalies, facial ab-
normalities, IUGR, mental retardation and other malfor-
mation including cardiac defects. To date, at least 29
prenatal cases with the 17p13.3 deletion syndrome have
been reported. Among them, only four cases presented
with CHD [20]. In our study, the case 11 with 17p13.3
deletion showed cardiac defects including DORV, VSD
and PA. These results suggested that MLPA technology
could comprehensively and rapidly detect pathogenic
CNVs in several different chromosomes regions.
Previous studies found that about 6 ~ 28 % of prenatal
22q11 deletions were inherited from one parent [21].
Two cases with pathological CNVs were inherited from
one parent in our study (Table 1). The SNP-array ana-
lysis indicated that the position of the fetus was identical
with that of the parent. One case in this study had
22q11 duplication inherited from his father (Table 2).
Though 22q11 CNVs were present in the three parents,
they did not display any mental disorder based on phys-
ical examination. Furthermore, their internal organs
especially heart revealed no abnormalities by sono-
graphic examination. Several reasons may explain the
difference in phenotypes with the same genetic changes,
such as allelic variation at the haploid locus, self-repair
and environmental effects [22, 23]. Since healthy carriers
of chromosomal deletions or duplications have 50 %Table 2 MLPA and SNP-array results of 11 fetuses with CHD






1 29 25 IAA,VSD 22q11.2 Del.
2 24 24 TGA, VSD 22q11.2 Del.
3 37 25 TA,VSD 22q11.2 Del.
4 23 27 TA,VSD 22q11.2 Del.
5 29 24 TOF 22q11.2 Del.
6 29 23 VSD 22q11.2 Del.
7 28 23 TOF, PA 22q11.2 Del.
8 26 23 DORV, VSD, PA 22q11.122q11.2 Del
9 31 24 AH,VSD 22q11.2 Dup.
10 29 24 IAA,VSD, ASD 22q13.3 Del.
11 26 22 DORV, VSD, PA 17p13.3 Del.
VSD ventricular septal defect, IAA interrupted aortic arch, TGA transposition of cond
AH aortic hypoplasia, ASD atrial septum defect, DORV double outlet right ventriclechance to pass on to the next generation in each preg-
nancy, two couples who had the fetus with pathogenic
CNVs in our study may have a high risk in their next
pregnancy. Among the three families, the mother of case
seven had a normal child with no CNVs, the mother of
case nine had a miscarriage and the mother of case eight
had not been pregnant again.
The proximal portion of chromosome 22q was a hot re-
gion for chromosomal rearrangement. Cat eye syndrome
(CES) is a rare chromosome disorder in human caused by
the duplication of chromosome 22q11. The CES critical
region covered approximately 2 Mb from the centromere
to the locus D22S57 [24], but the deletion of this region is
rarely reported. According to DECIPHER database
(https://decipher.sanger.ac.uk), only eight cases were de-
tected to carry genomic deletion encompassing the region,
and none of them displayed CHD. Kriek et al. [25] firstly
reported that a fetus, carrying different rearrangements on
chromosome 22q, including the deletion of CES critical
region, had the manifestation of developmental delay but
no history of cardiac problems. Kriek et al. also suggested
that the deletion of CES critical region had little clinical
relevance because the normal familial members were car-
rying this deletion. In our study, we firstly report a fetus
with CHD showing a deletion of 980 K spanning the CES
region from genomic position 17,067,005 to18,047,231
(Fig. 2). This deletion region contained 14 genes, including
six OMIM genes (CECR7, CECR2, CECR1, IL17RA,
XKR3, and SLC25A18). Xie et al. [26] identified thatSNP-array results Type of
mutationProbes Positon Size
CLTCL1 ~ LZTR1 18877787 ~ 21798907 2.92 M de novo
CLTCL1 ~ LZTR1 18877787 ~ 21462353 2.58 M de novo
CLTCL1 ~ LZTR1 18877787 ~ 21462353 2.58 M de novo
CLTCL1 ~ LZTR1 18895227 ~ 21462353 2.56 M de novo
CLTCL1 ~ LZTR1 18877787 ~ 21462353 2.58 M de novo
CLTCL1 ~ LZTR1 18895227 ~ 21462353 2.56 M de novo
CLTCL1 ~ DGCR8 18895227 ~ 20306993 1.4 M inherited
IL17RA,SLC25A18 17067005 ~ 18047231 980 k inherited
CLTCL1 ~ LZTR1 18623108 ~ 21462353 2.8 M inherited
ARSA, SHANK3 49045728 ~ 51169045 2.1 M de novo
RH3AL,GEMIN4, YWHAE 18901 ~ 2633324 2.61 M de novo
ucting arteries, TA truncus arteriosus, TOF trilogy of fallot, PA pulmonary atresia,
Fig. 2 SNP-array analysis of chromosome 22q11 in fetus 8. The analysis revealed a 980 kb heterozygous deletion mapping to position 17,067,005-
18,047,231 on chromosome 22q11. Some known genes within the region are indicated in the down panel
Zhang et al. Molecular Cytogenetics  (2015) 8:100 Page 5 of 7IL17RA was related to myocardial disease while there
were no other genes having been reported to be
related to cardiac disease. Besides the duplication of
CES region can cause the manifestation of CHD, our
finding firstly indicated a possible relationship be-
tween CHD and the deletion of CES region. Further
collecting of more cases is still needed to confirm if
the deletion of CES region may cause CHD.
Conclusion
In summary, this study confirmed that MLPA could rap-
idly and efficiently detect pathogenic CNVs associatedwith CHD in our cohort. Thus, it is an economical, fast
and accurate method for the prenatal genetic diagnosis of
CHD for clinical application.
Methods
Case recruitment
The study was performed at the Department of Prenatal
Diagnosis in Nanjing Maternity and Child Health Care
Hospital (Jiangsu, China) between 2011 and 2014. In our
hospital, the second trimester ultrasound screening was
carried out in all pregnancies. After structural heart de-
fects were found, prenatal echocardiography was offered
Zhang et al. Molecular Cytogenetics  (2015) 8:100 Page 6 of 7for detail diagnosis. In total, 225 fetuses presenting with
CHD were enrolled in the study. The distribution of
different clinical manifestations was shown in Table 1.
The CHD cases included in the study were: conotruncal
defects (85/225), septal defects (104/225), left-heart de-
fects (7/225), right-heart defect (1/225), and other heart
defects (28/225). In all 225 fetuses, 211 cases were with
isolated CHD, and the other 14 cases were with extra
cardiac anomalies. G-banding analysis was first carried
out in all 225 fetuses. Once chromosome abnormalities
had been excluded in a fetus with a CHD, the CNV of
chromosome 22q11 were investigated by MLPA. The
mean age of these pregnancies was 29 ± 4.33 years old
and the average gestation age at invasive prenatal diag-
nosis was 24 ± 2.56 weeks. All the pregnant women
signed the informed consent form. This study was
approved by the medicine ethics committee of Nanjing
Maternity and Child Health Care Hospital.Cytogenetic analysis
All samples of amniotic fluid and fetal cord blood were
detected using G-banding according to the standard
procedure described previously [27].Multiplex ligation-dependent probe amplification
Fetal DNA was extracted from uncultured amniotic fluid
or fetal blood cells according to the illustrations of the
QIAamp DNA Mini Kit (QIAGEN, Hilden, Germany).
The SALSA MLPA P250 kit was performed to detect
deletion or duplication of the 22q11 chromosomal re-
gion. This kit includes 24 probes targeting DiGeorge
syndrome region, five probes targeting cat eye syndrome
region, and 19 probes for DiGeorge anomaly related
chromosomal regions such as 22q13, 10p14, 8p23, 9q34,
17p13.3, and 4q34.
About 100 ~ 150 ng DNA of each sample was involved
in the experiment. MLPA analysis was performed following
the manufacturer’s instructions. The MLPA products were
examined by ABI 3130 genetic analyzer (Thermo Fisher,
USA) and quantitative data were analyzed using the soft-
ware of Coffalyser V8.0 (http://www.mlpa.com/coffalyser).
The 30 % increase or decrease of the relative peak area of
the probe showed the duplication or deletion of the
targeted region, respectively.SNP-array analysis
Fetus DNA was examined by Human cyto12 SNP-array
scanning (Illumina, USA), which comprised about
300,000 SNPs across the whole genome. SNP-array
experiments were carried out as previously described
[28] and molecular karyotype analysis was performed by
KaryoStudio Software V 1.3.11 (Illumina, USA).Consent
Written informed consent was obtained from the pregnant
women for publication of this paper. This research was
approved by the ethics committee of Nanjing Maternity
and Child Health Care Hospital.
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